Better Access Better Healthcare
We improve global healthcare through better access to medicine.
Abacus Medicine is firmly established among the market leaders in the European parallel distribution industry.
Abacus Medicine Pharma Services works with Clinical Trial Solutions and Commercial Partnerships.
Originalis is a parallel distributor of medicine operating in Germany and Ireland.
Pluripharm is a leading wholesaler in the Netherlands and offers a full line of medicines, medical devices and services to a range of customers.
We are innovative, dedicated
and we care.
The Abacus Medicine Group is built on a strong purpose. When we compete in the market, we help lower the prices on life-critical medicines so that they become more widely available.
The Abacus Medicine Group is a business. We operate commercially, and our activities provide jobs, careers and livelihoods for hundreds of people in dozens of countries.
But we are more than that. When we compete in the market, we help life-critical medicines become more widely available. This gives us a purpose beyond ourselves and is something we can be proud of.
Flemming Wagner
CEO & majority shareholder
Global locations
Employees
Packs sold in 2023
A career in the Abacus Medicine Group
Join an ambitious and diverse company.
We are always looking for new and dedicated colleagues.
Latest news
Sustainability Report 2023: Sustainability is an enabler of ambitious Access26 strategy
In 2023, sustainability became an enabler of our Access26 strategy – an important step towards ensuring a deeper integration of sustainability in all our processes and operations. Throughout the year, we also prepared for the upcoming Corporate Sustainability Reporting Directive, under which we need to report in 2026.
Abacus Medicine Group: Record full-year result
The Abacus Medicine Group exceeded the guidance ranges for both revenue and profitability in 2023. A combination of high demand in core sales markets and solid commercial execution drove organic revenue growth of 18% to EUR 1,210 million and EBITDA growth of 82% to EUR 47.5 million.
The main shareholders in Abacus Medicine A/S nominate Jens Harsaae as new Chairman of the Board
Jens Harsaae is being nominated as new Chairman of Abacus Medicine A/S by the main shareholders.